Heron’s HTX-011 meets postoperative pain endpoints

Heron Therapeutics Inc. (NASDAQ:HRTX) gained $5.80 (27%) to $27.30 on Monday after it said HTX-011 met the primary and key secondary endpoints

Read the full 229 word article

User Sign In